#1 Clinical Trials Search in Europe

Dimethyl Fumarate

Dimethyl fumarate, also known as Tecfidera, is a medication that has been the subject of numerous clinical trials, primarily for its use in treating multiple sclerosis (MS). These trials have explored its efficacy, safety, and mechanisms of action in relapsing-remitting MS, as well as its potential applications in other conditions such as acute ischemic stroke. This article summarizes key findings from various clinical trials investigating dimethyl fumarate and its impact on patients with MS and other neurological conditions.

Table of Contents

What is Dimethyl Fumarate?

Dimethyl fumarate, also known by its brand names Tecfidera, DMF, or BG00012, is an oral medication used in the treatment of multiple sclerosis (MS)[1]. It is an immune-modulating drug, which means it works by affecting the way your immune system functions[2]. Dimethyl fumarate has been approved by regulatory agencies, including the European Medicines Agency and the U.S. Food and Drug Administration, for the treatment of relapsing forms of multiple sclerosis in adults[3].

What Conditions Does Dimethyl Fumarate Treat?

Dimethyl fumarate is primarily used to treat:

  • Relapsing-Remitting Multiple Sclerosis (RRMS): This is the most common form of MS, characterized by periods of symptom flare-ups followed by periods of recovery[4].
  • Secondary Progressive Multiple Sclerosis (SPMS): Some studies are investigating its use in this form of MS, which follows RRMS and involves more steady progression of symptoms[5].

Interestingly, research is also being conducted to explore the potential use of dimethyl fumarate in treating acute ischemic stroke, which is a type of stroke caused by a blockage in blood flow to the brain[6]. However, this use is still experimental and not yet approved.

How Does Dimethyl Fumarate Work?

The exact mechanism of action of dimethyl fumarate is not fully understood, but research suggests it works in several ways:

  1. Neuroprotection: It is believed to enhance the nuclear factor erythroid 2 related factor 2 (Nrf2) transcriptional pathway. This pathway helps protect nerve cells from damage caused by oxidative stress, which is an imbalance between harmful molecules called free radicals and the body’s ability to counteract their effects[4].
  2. Anti-inflammatory effects: Dimethyl fumarate may inhibit the activation of certain immune cells and reduce the production of inflammatory molecules[4].
  3. Immune system modulation: It affects various types of immune cells, potentially altering their behavior to reduce the autoimmune attack on the nervous system that occurs in MS[2].

How is Dimethyl Fumarate Administered?

Dimethyl fumarate is taken orally in capsule form. The typical dosing schedule is as follows:

  • Initial dose: 120 mg twice daily for the first 7 days
  • Maintenance dose: 240 mg twice daily thereafter[7]

It’s important to take the medication as prescribed by your healthcare provider. The gradual increase in dosage is designed to help reduce gastrointestinal side effects that some patients may experience when starting the medication.

Effectiveness of Dimethyl Fumarate

Clinical trials have shown that dimethyl fumarate is effective in treating relapsing forms of multiple sclerosis. Specifically, it has been found to:

  • Reduce the number of relapses in patients with RRMS
  • Decrease the number of new or enlarging brain lesions seen on MRI scans
  • Potentially slow the progression of disability[3][8]

These effects are typically measured using tools such as the Expanded Disability Status Scale (EDSS), which assesses physical disability, and MRI scans, which can visualize changes in the brain and spinal cord.

Side Effects and Tolerability

Like all medications, dimethyl fumarate can cause side effects. The most common side effects include:

  • Gastrointestinal issues: Such as nausea, diarrhea, abdominal pain, and vomiting. These symptoms are often most pronounced when starting the medication and may improve over time[7].
  • Flushing: A sensation of warmth or redness in the skin, particularly on the face and upper body.
  • Decreased white blood cell counts: Regular blood tests are typically recommended to monitor this[1].

To help manage gastrointestinal side effects, your doctor may recommend taking the medication with food or using symptomatic therapies (medications to treat specific symptoms). In some cases, temporary dose reductions may be necessary[7].

Ongoing Research and Future Directions

Research on dimethyl fumarate is ongoing, with several areas of focus:

  • Long-term safety and efficacy: Studies are tracking patients over extended periods to understand the long-term effects of the medication[1].
  • Effects on the gut microbiome: Some research is investigating how dimethyl fumarate might affect the bacteria in the intestines, which could have implications for its overall effects on the immune system[5].
  • Use in other conditions: As mentioned earlier, studies are exploring its potential use in conditions like acute ischemic stroke[6].
  • Mechanisms of action: Ongoing research aims to better understand exactly how dimethyl fumarate works in the body, which could lead to improved treatments in the future[4].

As with any medication, it’s crucial to discuss the potential benefits and risks of dimethyl fumarate with your healthcare provider. They can provide personalized advice based on your specific medical history and condition.

Aspect Details
Primary Use Treatment of relapsing forms of multiple sclerosis
Mechanism of Action Enhances Nrf2 transcriptional pathway, anti-inflammatory effects, inhibits NFκB translocation
Common Side Effects Gastrointestinal events (nausea, diarrhea, abdominal pain), flushing
Efficacy Measures Reduction in annualized relapse rate, decrease in new/enlarging MRI lesions, improvement in EDSS scores
Ongoing Research Potential use in acute ischemic stroke, effects on gut microbiota, neuroprotective mechanisms
Administration Oral capsules, typically 240 mg twice daily after initial titration
Patient Monitoring Regular assessments of disease activity, MRI scans, blood tests for lymphocyte counts and liver function

FAQ

  • What is dimethyl fumarate and how does it work in multiple sclerosis? Dimethyl fumarate is a medication used to treat relapsing forms of multiple sclerosis. It is believed to work by enhancing the nuclear factor erythroid 2 related factor 2 (Nrf2) transcriptional pathway, which helps counter oxidative stress. It also has anti-inflammatory properties and may inhibit certain immune system processes that contribute to MS symptoms.
  • What are the main side effects of dimethyl fumarate? The most common side effects of dimethyl fumarate are gastrointestinal-related events, such as nausea, diarrhea, abdominal pain, and vomiting. Some patients may require symptomatic therapy to manage these side effects. Other potential side effects can include flushing, decreased white blood cell counts, and liver enzyme elevations.
  • How effective is dimethyl fumarate in treating multiple sclerosis? Clinical trials have shown that dimethyl fumarate can reduce the annualized relapse rate in patients with relapsing-remitting MS. It has also been found to decrease the number of new or enlarging brain lesions seen on MRI scans. The effectiveness varies among individuals, but many patients experience a reduction in disease activity and progression.
  • Are there any ongoing studies exploring dimethyl fumarate's use in other conditions? Yes, there are ongoing studies investigating the potential use of dimethyl fumarate in other conditions. For example, some trials are exploring its effects in acute ischemic stroke patients. These studies aim to determine if dimethyl fumarate's neuroprotective and anti-inflammatory properties could be beneficial in reducing stroke-related damage and improving outcomes.
  • How long do patients typically stay on dimethyl fumarate treatment? The duration of dimethyl fumarate treatment can vary. In clinical trials, patients have been studied for periods ranging from 12 weeks to over a year. Long-term observational studies are ongoing to assess the medication's effectiveness and safety over extended periods. The decision to continue or discontinue treatment is typically made by the patient and their healthcare provider based on individual response and tolerability.

Ongoing Clinical Trials on Dimethyl Fumarate

  • Study on Stopping Dimethyl Fumarate and Drug Combination in Patients Aged 55+ with Inactive Relapsing-Remitting Multiple Sclerosis

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Dimethyl Fumarate for Patients with Mild Cognitive Impairment and Alzheimer’s Disease

    Recruiting

    1 1 1
    Investigated drugs:
    Poland

  • Study on the Safety and Effectiveness of AZD0305 Alone and with Other Cancer Drugs for Adults with Relapsed or Refractory Multiple Myeloma

    Recruiting

    1 1 1
    Investigated drugs:
    France Germany Spain

  • Study of dimethyl fumarate to slow the progression of geographic atrophy in patients with age-related macular degeneration (dry form)

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Anti-CD20 Therapy and Drug Combination for Patients with Relapsing-Remitting Multiple Sclerosis

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effects of Dimethyl Fumarate for Patients with Adrenomyeloneuropathy

    Not recruiting

    1 1 1
    Investigated drugs:
    Spain

  • Study Comparing Fedratinib with Drug Combination for Myelofibrosis in Patients Previously Treated with Ruxolitinib

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Hungary +4

  • Study on the Effectiveness and Tolerability of Ofatumumab Compared to a Drug Combination for Patients with Newly Diagnosed Relapsing Multiple Sclerosis

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Spain

  • Study on Metformin for Delaying Progression in Non-Active Progressive Multiple Sclerosis Patients

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Study on the Effects of Dimethyl Fumarate for Patients with Friedreich’s Ataxia

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Italy

Glossary

  • Relapsing-Remitting Multiple Sclerosis (RRMS): A form of multiple sclerosis characterized by clearly defined attacks of new or increasing neurologic symptoms followed by periods of partial or complete recovery (remissions).
  • Annualized Relapse Rate (ARR): The number of confirmed MS relapses a patient experiences in a year, used as a measure of disease activity and treatment effectiveness.
  • Expanded Disability Status Scale (EDSS): A method of quantifying disability in multiple sclerosis, ranging from 0 to 10, with higher scores indicating more severe disability.
  • Gadolinium-Enhancing (GdE) Lesions: Areas of active inflammation in the brain or spinal cord that can be seen on MRI scans after the injection of a contrast agent called gadolinium.
  • T2 Hyperintense Lesions: Areas of damage in the brain or spinal cord that appear bright on T2-weighted MRI scans, indicating past or present inflammation or tissue damage in MS.
  • Nrf2 Transcriptional Pathway: A cellular mechanism that regulates the expression of antioxidant proteins that protect against oxidative damage triggered by injury and inflammation.
  • Peripheral Blood Mononuclear Cells (PBMCs): Blood cells with a single round nucleus, including lymphocytes and monocytes, which are important components of the immune system.
  • National Institutes of Health Stroke Scale (NIHSS): A tool used to objectively quantify the impairment caused by a stroke, with scores ranging from 0 to 42, where higher scores indicate more severe impairment.
  • Modified Rankin Scale (mRS): A scale for measuring the degree of disability or dependence in daily activities for people who have suffered a stroke or other neurological disabilities.
  • Cerebrospinal Fluid (CSF): A clear, colorless fluid that surrounds the brain and spinal cord, often analyzed in MS research to measure markers of disease activity and treatment response.

References

  1. https://clinicaltrials.gov/study/NCT02047097
  2. https://clinicaltrials.gov/study/NCT02461069
  3. https://clinicaltrials.gov/study/NCT02901106
  4. https://clinicaltrials.gov/study/NCT02675413
  5. https://clinicaltrials.gov/study/NCT03092544
  6. https://clinicaltrials.gov/study/NCT04890353
  7. https://clinicaltrials.gov/study/NCT02125604
  8. https://clinicaltrials.gov/study/NCT05658484